How it works: Abiraterone inhibits CYP17 enzyme involved in testosterone production, significantly lowering androgen levels and slowing prostate cancer growth.
Who it’s for:
– Patients with metastatic castration-resistant prostate cancer (mCRPC)
– Men with high-risk disease progression
– Those previously treated with chemotherapy (docetaxel) or hormone therapy
– For use in combination with prednisone
– Metastatic castration-resistant prostate cancer (mCRPC)
– Metastatic hormone-sensitive prostate cancer (mHSPC), with corticosteroids
ABIRAPRO is taken orally on an empty stomach, typically at 1000 mg (4 tablets) once daily. It must be combined with prednisone to reduce adverse effects. Treatment is long-term and must be supervised by an oncologist.
Contraindicated in hypersensitivity, severe liver dysfunction, and pregnancy (in female partners).
Possible side effects include hypokalaemia, hypertension, oedema, and elevated liver enzymes. Regular blood tests and blood pressure monitoring are essential.
